breast, colon, or rectal cancer.

Oral capecitabine is indicated for the treatment of metastatic breast cancer that is refractory to paclitaxel and anthracycline therapy. It is also indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred.Peak plasma levels occur in 90 minutes, and elimination half-life is 45 minutes. Food reduces the rate and extent of absorption.

Peak plasma levels occur in 90 minutes, and elimination half-life is 45 minutes. Food reduces the rate and extent of absorption.

hypersensitivity and severe renal impairment (creatinine clearance less than 30 milliliters/minute by Cockroft and Gault equation)

D

Avoided, It is recommended that nursing be discontinued due to the potential for serious adverse reactions in nursing infants

Although minimal side effects were claimed, significant adverse effects have been reported in some patients, including altered coagulation or bleeding, hand-foot syndrome, diarrhea, nausea, vomiting, edema, and stomatitis.

Adults: Metastatic breast cancer and metastatic colorectal cancer: 2500 mg/m2 daily in two divided doses for 2 weeks with a 1-week rest period. Cycles repeated every 3 weeks